title: Subcutaneously administered Repronex in female patients undergoing in vitro fertilization is as effective and well tolerated as intramuscular menotropin treatment. Repronex SC, IVF Study Group.
abstract: OBJECTIVE
  To determine the efficacy and safety of Repronex SC as compared with Repronex IM and Pergonal IM in patients undergoing IVF.
  
  
  METHODS
  Open-label, randomized, parallel-group, multicenter study.
  
  
  METHODS
  Fifteen academic and private fertility clinics with IVF experience.
  
  
  METHODS
  Premenopausal women with regular ovulatory menstrual cycles undergoing IVF for infertility attributable to tubal factors, endometriosis (stage I or II), or unknown factors.
  
  
  METHODS
  Down-regulation with leuprolide acetate followed by up to 12 days of treatments with gonadotropins, hCG administration, oocyte retrieval, and embryo transplant.
  
  
  METHODS
  Mean number of oocytes retrieved, chemical, clinical, and continuing pregnancies, incidence of oocyte retrieval and embryo transfer, and peak serum E2 concentrations.
  
  
  RESULTS
  There were no significant differences among the treatment groups except for a higher percentage of continuing pregnancies in the Repronex SC group. Gonadotropin therapy was well tolerated in all three treatment groups. The Repronex SC group had a significantly higher incidence of transient mild/moderate injection site reactions during the first few days of therapy.
  
  
  CONCLUSIONS
  Repronex SC is comparable in therapeutic effectiveness and safety to Repronex IM and Pergonal IM in patients undergoing IVF and provides an alternative route of injection for self-administration of gonadotropin.
authors.affiliation: Penn Reproductive Associates, USA.
authors.forename: B
authors.initials: B
authors.lastname: Gocial
authors.forename: W R
authors.initials: WR
authors.lastname: Keye
authors.forename: S H
authors.initials: SH
authors.lastname: Fein
authors.forename: R V
authors.initials: RV
authors.lastname: Nardi
mesh_terms: D000293:Adolescent; D000328:Adult; D015536:Down-Regulation; D004624:Embryo Transfer; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000627:therapeutic use*; D005307:Fertilization in Vitro; D006062:Gonadotropins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use; D008596:Menotropins / Q000627:therapeutic use; D010062:Ovulation Induction; D017697:Premenopause
chemical_list: D005300:Fertility Agents, Female; D006062:Gonadotropins; D008596:Menotropins; D016729:Leuprolide